FIG A1.

Updated PFS (blinded independent central review) by prespecified and exploratory, post hoc subgroups. ^aHRs and 95% CIs were not calculated if the subgroup had < 20 events. ^bThree patients with missing WHO PS were included in the PS 1 subgroup. ^cThe other race category includes American Indian or Alaskan Native (n = 9), Native Hawaiian or Other Pacific Islander (n = 2), and Other (n = 1). ^dThe subgroup includes 35 patients with tumors harboring EGFR mutations and, on the basis of local testing, eight patients with tumors harboring ALK alterations. ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; HR, hazard ratio; NSCLC, non–small-cell lung cancer; PD-L1, programmed cell death-ligand 1; PFS, progression-free survival; PS, performance status.